Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Stability of different influenza subtypes: How can high hydrostatic pressure be a useful tool for vaccine development?

Dumard CH, Barroso SPC, Santos ACV, Alves NS, Couceiro JNSS, Gomes AMO, Santos PS, Silva JL, Oliveira AC.

Biophys Chem. 2017 Dec;231:116-124. doi: 10.1016/j.bpc.2017.04.002. Epub 2017 Apr 6.

PMID:
28410940
2.

Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.

Petiot E, Proust A, Traversier A, Durous L, Dappozze F, Gras M, Guillard C, Balloul JM, Rosa-Calatrava M.

Vaccine. 2018 May 24;36(22):3101-3111. doi: 10.1016/j.vaccine.2017.03.102. Epub 2017 May 29.

PMID:
28571695
3.

Replication and transcription activities of ribonucleoprotein complexes reconstituted from avian H5N1, H1N1pdm09 and H3N2 influenza A viruses.

Ngai KL, Chan MC, Chan PK.

PLoS One. 2013 Jun 4;8(6):e65038. doi: 10.1371/journal.pone.0065038. Print 2013.

4.

Pressure-Inactivated Virus: A Promising Alternative for Vaccine Production.

Silva JL, Barroso SP, Mendes YS, Dumard CH, Santos PS, Gomes AM, Oliveira AC.

Subcell Biochem. 2015;72:301-18. doi: 10.1007/978-94-017-9918-8_15.

PMID:
26174388
5.

A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Baz M, Paskel M, Matsuoka Y, Zengel JR, Cheng X, Treanor JJ, Jin H, Subbarao K.

J Virol. 2015 Jul;89(13):6907-17. doi: 10.1128/JVI.00280-15. Epub 2015 Apr 22.

6.

A novel pathogenic mechanism of highly pathogenic avian influenza H5N1 viruses involves hemagglutinin mediated resistance to serum innate inhibitors.

Panaampon J, Ngaosuwankul N, Suptawiwat O, Noisumdaeng P, Sangsiriwut K, Siridechadilok B, Lerdsamran H, Auewarakul P, Pooruk P, Puthavathana P.

PLoS One. 2012;7(5):e36318. doi: 10.1371/journal.pone.0036318. Epub 2012 May 1.

7.

Cross-Species Infectivity of H3N8 Influenza Virus in an Experimental Infection in Swine.

Solórzano A, Foni E, Córdoba L, Baratelli M, Razzuoli E, Bilato D, Martín del Burgo MÁ, Perlin DS, Martínez J, Martínez-Orellana P, Fraile L, Chiapponi C, Amadori M, del Real G, Montoya M.

J Virol. 2015 Nov;89(22):11190-202. doi: 10.1128/JVI.01509-15. Epub 2015 Aug 26.

8.

Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.

Snyder MH, Clements ML, Betts RF, Dolin R, Buckler-White AJ, Tierney EL, Murphy BR.

J Clin Microbiol. 1986 May;23(5):852-7.

9.

Full inactivation of human influenza virus by high hydrostatic pressure preserves virus structure and membrane fusion while conferring protection to mice against infection.

Dumard CH, Barroso SP, de Oliveira GA, Carvalho CA, Gomes AM, Couceiro JN, Ferreira DF, Nico D, Oliveira AC, Silva JL, Santos PS.

PLoS One. 2013 Nov 25;8(11):e80785. doi: 10.1371/journal.pone.0080785. eCollection 2013.

10.

Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.

Dimmock NJ, Rainsford EW, Scott PD, Marriott AC.

J Virol. 2008 Sep;82(17):8570-8. doi: 10.1128/JVI.00743-08. Epub 2008 Jun 25.

11.

Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model.

Vergara-Alert J, Argilaguet JM, Busquets N, Ballester M, Martín-Valls GE, Rivas R, López-Soria S, Solanes D, Majó N, Segalés J, Veljkovic V, Rodríguez F, Darji A.

PLoS One. 2012;7(7):e40524. doi: 10.1371/journal.pone.0040524. Epub 2012 Jul 16.

12.

Tropism and infectivity of influenza virus, including highly pathogenic avian H5N1 virus, in ferret tracheal differentiated primary epithelial cell cultures.

Zeng H, Goldsmith CS, Maines TR, Belser JA, Gustin KM, Pekosz A, Zaki SR, Katz JM, Tumpey TM.

J Virol. 2013 Mar;87(5):2597-607. doi: 10.1128/JVI.02885-12. Epub 2012 Dec 19.

13.

The influenza virus enigma.

Salomon R, Webster RG.

Cell. 2009 Feb 6;136(3):402-10. doi: 10.1016/j.cell.2009.01.029.

14.

Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins.

Sundararajan A, Ganapathy R, Huan L, Dunlap JR, Webby RJ, Kotwal GJ, Sangster MY.

Antiviral Res. 2010 Oct;88(1):1-9. doi: 10.1016/j.antiviral.2010.06.014. Epub 2010 Jul 14.

PMID:
20637243
15.

The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines.

O'Donnell CD, Vogel L, Matsuoka Y, Jin H, Subbarao K.

J Virol. 2014 Nov;88(21):12374-84. doi: 10.1128/JVI.01107-14. Epub 2014 Aug 13.

16.

Equine and Canine Influenza H3N8 Viruses Show Minimal Biological Differences Despite Phylogenetic Divergence.

Feng KH, Gonzalez G, Deng L, Yu H, Tse VL, Huang L, Huang K, Wasik BR, Zhou B, Wentworth DE, Holmes EC, Chen X, Varki A, Murcia PR, Parrish CR.

J Virol. 2015 Jul;89(13):6860-73. doi: 10.1128/JVI.00521-15. Epub 2015 Apr 22.

17.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
18.

Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.

Bragstad K, Martel CJ, Thomsen JS, Jensen KL, Nielsen LP, Aasted B, Fomsgaard A.

Influenza Other Respir Viruses. 2011 Jan;5(1):13-23. doi: 10.1111/j.1750-2659.2010.00177.x. Epub 2010 Nov 3.

19.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

20.

Genetic and biological characterisation of an avian-like H1N2 swine influenza virus generated by reassortment of circulating avian-like H1N1 and H3N2 subtypes in Denmark.

Trebbien R, Bragstad K, Larsen LE, Nielsen J, Bøtner A, Heegaard PM, Fomsgaard A, Viuff B, Hjulsager CK.

Virol J. 2013 Sep 18;10:290. doi: 10.1186/1743-422X-10-290.

Supplemental Content

Support Center